Regeneron Pharmaceuticals (REGN) Total Debt (2014 - 2026)

Regeneron Pharmaceuticals has reported Total Debt for 9 years, with the latest figure at $2.0 billion in Q2 2026.

• On a quarterly basis, Total Debt changed 0.1% year-over-year to $2.0 billion in Q2 2026; TTM through Jun 2026 was $2.0 billion, a 0.1% change from a year earlier, with the FY2025 full-year figure at $2.0 billion, changed 0.08% from the prior year.
• Total Debt was $2.0 billion for Q2 2026 at Regeneron Pharmaceuticals, roughly flat from $2.0 billion in the prior quarter.
• The five-year high for Total Debt was $2.0 billion in Q2 2026, with the low at $2.0 billion in Q1 2022.
• Average Total Debt over 5 years is $2.0 billion, with a median of $2.0 billion recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Total Debt grew 0.1% in 2025, then climbed 0.07% in 2026.
• Over 5 years, Total Debt stood at $2.0 billion in 2022, then gained by 0.08% to $2.0 billion in 2023, then increased by 0.08% to $2.0 billion in 2024, then grew by 0.08% to $2.0 billion in 2025, then gained by 0.05% to $2.0 billion in 2026.
• The last three Total Debt figures came in at $2.0 billion (Q2 2026), $2.0 billion (Q1 2026), and $2.0 billion (Q4 2025), per Business Quant data.